ID   TIRAP_HUMAN             Reviewed;         221 AA.
AC   P58753; B3KW65; Q56UH9; Q56UI0; Q8N5E5;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2004, sequence version 2.
DT   28-JUN-2023, entry version 185.
DE   RecName: Full=Toll/interleukin-1 receptor domain-containing adapter protein;
DE            Short=TIR domain-containing adapter protein;
DE   AltName: Full=Adaptor protein Wyatt;
DE   AltName: Full=MyD88 adapter-like protein;
DE            Short=MyD88-2;
GN   Name=TIRAP; Synonyms=MAL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), MUTAGENESIS OF PRO-125, AND VARIANT
RP   ASN-55.
RC   TISSUE=Dendritic cell;
RX   PubMed=11544529; DOI=10.1038/35092578;
RA   Fitzgerald K.A., Palsson-McDermott E.M., Bowie A.G., Jefferies C.A.,
RA   Mansell A.S., Brady G., Brint E., Dunne A., Gray P., Harte M.T.,
RA   McMurray D., Smith D.E., Sims J.E., Bird T.A., O'Neill L.A.J.;
RT   "Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal
RT   transduction.";
RL   Nature 413:78-83(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), MUTAGENESIS OF PRO-125, AND
RP   INTERACTION WITH EIF2AK2.
RX   PubMed=11526399; DOI=10.1038/ni0901-835;
RA   Horng T., Barton G.M., Medzhitov R.;
RT   "TIRAP: an adapter molecule in the Toll signaling pathway.";
RL   Nat. Immunol. 2:835-841(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Kirk P.B., Pereira J.P., Bazan J.F.;
RT   "Characterization and structural analysis of TIR domain-containing adaptor
RT   protein Wyatt.";
RL   Submitted (AUG-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RA   Hardy M.P., O'Neill L.A.J.;
RT   "Two isoforms of MAL, generated by alternative splicing, are found in
RT   humans but not mice.";
RL   Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=18810425; DOI=10.1007/s00251-008-0332-0;
RA   Nakajima T., Ohtani H., Satta Y., Uno Y., Akari H., Ishida T., Kimura A.;
RT   "Natural selection in the TLR-related genes in the course of primate
RT   evolution.";
RL   Immunogenetics 60:727-735(2008).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   ASN-55.
RC   TISSUE=Brain, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-9; TRP-13; ASN-96 AND
RP   LEU-180.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   INTERACTION WITH TBK1.
RX   PubMed=14530355; DOI=10.4049/jimmunol.171.8.4304;
RA   Sato S., Sugiyama M., Yamamoto M., Watanabe Y., Kawai T., Takeda K.,
RA   Akira S.;
RT   "Toll/IL-1 receptor domain-containing adapter inducing IFN-beta (TRIF)
RT   associates with TNF receptor-associated factor 6 and TANK-binding kinase 1,
RT   and activates two distinct transcription factors, NF-kappa B and IFN-
RT   regulatory factor-3, in the Toll-like receptor signaling.";
RL   J. Immunol. 171:4304-4310(2003).
RN   [12]
RP   PHOSPHORYLATION BY BTK, AND UBIQUITINATION.
RX   PubMed=16415872; DOI=10.1038/ni1299;
RA   Mansell A., Smith R., Doyle S.L., Gray P., Fenner J.E., Crack P.J.,
RA   Nicholson S.E., Hilton D.J., O'Neill L.A., Hertzog P.J.;
RT   "Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor
RT   signaling by mediating Mal degradation.";
RL   Nat. Immunol. 7:148-155(2006).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH BMX.
RX   PubMed=18292575; DOI=10.4049/jimmunol.180.5.3485;
RA   Semaan N., Alsaleh G., Gottenberg J.E., Wachsmann D., Sibilia J.;
RT   "Etk/BMX, a Btk family tyrosine kinase, and Mal contribute to the cross-
RT   talk between MyD88 and FAK pathways.";
RL   J. Immunol. 180:3485-3491(2008).
RN   [14]
RP   FUNCTION, INTERACTION WITH MYD88, VARIANT ASN-96, AND CHARACTERIZATION OF
RP   VARIANTS PRO-9; TRP-13; ASN-96; LEU-180 AND ILE-197.
RX   PubMed=19509286; DOI=10.1074/jbc.m109.014886;
RA   Nagpal K., Plantinga T.S., Wong J., Monks B.G., Gay N.J., Netea M.G.,
RA   Fitzgerald K.A., Golenbock D.T.;
RT   "A TIR domain variant of MyD88 adapter-like (Mal)/TIRAP results in loss of
RT   MyD88 binding and reduced TLR2/TLR4 signaling.";
RL   J. Biol. Chem. 284:25742-25748(2009).
RN   [15]
RP   INTERACTION WITH MYD88, AND SUBCELLULAR LOCATION.
RX   PubMed=19948740; DOI=10.1074/jbc.m109.069385;
RA   Wan T., Liu T., Zhang H., Tang S., Min W.;
RT   "AIP1 functions as Arf6-GAP to negatively regulate TLR4 signaling.";
RL   J. Biol. Chem. 285:3750-3757(2010).
RN   [16]
RP   PHOSPHORYLATION BY IRAK1 AND IRAK4.
RX   PubMed=20400509; DOI=10.1074/jbc.m109.098137;
RA   Dunne A., Carpenter S., Brikos C., Gray P., Strelow A., Wesche H.,
RA   Morrice N., O'Neill L.A.;
RT   "IRAK1 and IRAK4 promote phosphorylation, ubiquitination, and degradation
RT   of MyD88 adaptor-like (Mal).";
RL   J. Biol. Chem. 285:18276-18282(2010).
RN   [17]
RP   INTERACTION WITH RAGE/AGER, AND FUNCTION.
RX   PubMed=21829704; DOI=10.1371/journal.pone.0023132;
RA   Sakaguchi M., Murata H., Yamamoto K., Ono T., Sakaguchi Y., Motoyama A.,
RA   Hibino T., Kataoka K., Huh N.H.;
RT   "TIRAP, an adaptor protein for TLR2/4, transduces a signal from RAGE
RT   phosphorylated upon ligand binding.";
RL   PLoS ONE 6:e23132-e23132(2011).
RN   [18]
RP   INTERACTION WITH B.MELITENSIS PROTEIN TCPB (MICROBIAL INFECTION).
RX   PubMed=24265315; DOI=10.1074/jbc.m113.523274;
RA   Alaidarous M., Ve T., Casey L.W., Valkov E., Ericsson D.J., Ullah M.O.,
RA   Schembri M.A., Mansell A., Sweet M.J., Kobe B.;
RT   "Mechanism of bacterial interference with TLR4 signaling by Brucella
RT   Toll/interleukin-1 receptor domain-containing protein TcpB.";
RL   J. Biol. Chem. 289:654-668(2014).
RN   [19]
RP   INTERACTION WITH B.MELITENSIS PROTEIN TCPB (MICROBIAL INFECTION).
RX   PubMed=27311859; DOI=10.1016/j.bbrc.2016.06.064;
RA   Li W., Ke Y., Wang Y., Yang M., Gao J., Zhan S., Xinying D., Huang L.,
RA   Li W., Chen Z., Li J.;
RT   "Brucella TIR-like protein TcpB/Btp1 specifically targets the host adaptor
RT   protein MAL/TIRAP to promote infection.";
RL   Biochem. Biophys. Res. Commun. 477:509-514(2016).
RN   [20] {ECO:0000312|PDB:2Y92}
RP   X-RAY CRYSTALLOGRAPHY (3.01 ANGSTROMS) OF 79-221, SUBUNIT, AND DISULFIDE
RP   BONDS.
RX   PubMed=21873236; DOI=10.1073/pnas.1104780108;
RA   Valkov E., Stamp A., Dimaio F., Baker D., Verstak B., Roversi P.,
RA   Kellie S., Sweet M.J., Mansell A., Gay N.J., Martin J.L., Kobe B.;
RT   "Crystal structure of Toll-like receptor adaptor MAL/TIRAP reveals the
RT   molecular basis for signal transduction and disease protection.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:14879-14884(2011).
RN   [21] {ECO:0000312|PDB:4LQD}
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF 81-221, INTERACTION WITH
RP   B.MELITENSIS TCPB (MICROBIAL INFECTION), DOMAIN (MICROBIAL INFECTION), AND
RP   DISULFIDE BONDS.
RX   PubMed=24275656; DOI=10.1074/jbc.m113.523407;
RA   Snyder G.A., Deredge D., Waldhuber A., Fresquez T., Wilkins D.Z.,
RA   Smith P.T., Durr S., Cirl C., Jiang J., Jennings W., Luchetti T.,
RA   Snyder N., Sundberg E.J., Wintrode P., Miethke T., Xiao T.S.;
RT   "Crystal structures of the Toll/Interleukin-1 receptor (TIR) domains from
RT   the Brucella protein TcpB and host adaptor TIRAP reveal mechanisms of
RT   molecular mimicry.";
RL   J. Biol. Chem. 289:669-679(2014).
RN   [22]
RP   VARIANT LEU-180, POLYMORPHISM, INTERACTION WITH MYD88 AND TLR2, AND
RP   HOMODIMERIZATION.
RX   PubMed=17322885; DOI=10.1038/ng1976;
RA   Khor C.C., Chapman S.J., Vannberg F.O., Dunne A., Murphy C., Ling E.Y.,
RA   Frodsham A.J., Walley A.J., Kyrieleis O., Khan A., Aucan C., Segal S.,
RA   Moore C.E., Knox K., Campbell S.J., Lienhardt C., Scott A., Aaby P.,
RA   Sow O.Y., Grignani R.T., Sillah J., Sirugo G., Peshu N., Williams T.N.,
RA   Maitland K., Davies R.J.O., Kwiatkowski D.P., Day N.P., Yala D.,
RA   Crook D.W., Marsh K., Berkley J.A., O'Neill L.A.J., Hill A.V.S.;
RT   "A Mal functional variant is associated with protection against invasive
RT   pneumococcal disease, bacteremia, malaria and tuberculosis.";
RL   Nat. Genet. 39:523-528(2007).
RN   [23]
RP   VARIANT LEU-180, AND POLYMORPHISM.
RX   PubMed=18305471; DOI=10.1038/ng0308-261;
RA   Nejentsev S., Thye T., Szeszko J.S., Stevens H., Balabanova Y.,
RA   Chinbuah A.M., Hibberd M., van de Vosse E., Alisjahbana B., van Crevel R.,
RA   Ottenhoff T.H., Png E., Drobniewski F., Todd J.A., Seielstad M.,
RA   Horstmann R.D.;
RT   "Analysis of association of the TIRAP (MAL) S180L variant and tuberculosis
RT   in three populations.";
RL   Nat. Genet. 40:261-262(2008).
RN   [24]
RP   VARIANT LEU-180, AND POLYMORPHISM.
RX   PubMed=19602285; DOI=10.1186/1471-2350-10-65;
RA   Hamann L., Kumpf O., Schuring R.P., Alpsoy E., Bedu-Addo G., Bienzle U.,
RA   Oskam L., Mockenhaupt F.P., Schumann R.R.;
RT   "Low frequency of the TIRAP S180L polymorphism in Africa, and its potential
RT   role in malaria, sepsis, and leprosy.";
RL   BMC Med. Genet. 10:65-65(2009).
CC   -!- FUNCTION: Adapter involved in TLR2, TLR4 and RAGE signaling pathways in
CC       the innate immune response. Acts via IRAK2 and TRAF-6, leading to the
CC       activation of NF-kappa-B, MAPK1, MAPK3 and JNK, and resulting in
CC       cytokine secretion and the inflammatory response. Positively regulates
CC       the production of TNF-alpha (TNF) and interleukin-6 (IL6).
CC       {ECO:0000269|PubMed:18292575, ECO:0000269|PubMed:19509286,
CC       ECO:0000269|PubMed:21829704}.
CC   -!- SUBUNIT: Homodimer (PubMed:17322885). Also forms heterodimers with
CC       MYD88 (PubMed:17322885). May interact with PIK3AP1 (By similarity).
CC       Interacts with TLR4 and IRAK2 via their respective TIR domains.
CC       Interacts with BMX and TBK1. Interacts with EIF2AK2. Does not interact
CC       with IRAK1, nor TLR9. Interacts with TLR2 (PubMed:17322885). Interacts
CC       with RAGE/AGER (PubMed:21829704). {ECO:0000250,
CC       ECO:0000269|PubMed:11526399, ECO:0000269|PubMed:14530355,
CC       ECO:0000269|PubMed:17322885, ECO:0000269|PubMed:18292575,
CC       ECO:0000269|PubMed:19509286, ECO:0000269|PubMed:19948740,
CC       ECO:0000269|PubMed:21829704, ECO:0000269|PubMed:21873236}.
CC   -!- SUBUNIT: (Microbial infection) In case of infection, interacts with
CC       B.melitensis protein TcpB (AC Q8YF53); TcpB abolishes the TLR4-TIRAP
CC       interaction and downstream signaling. {ECO:0000269|PubMed:24275656,
CC       ECO:0000269|PubMed:27311859}.
CC   -!- INTERACTION:
CC       P58753; Q15109: AGER; NbExp=9; IntAct=EBI-528644, EBI-1646426;
CC       P58753; P10398: ARAF; NbExp=2; IntAct=EBI-528644, EBI-365961;
CC       P58753; Q96A33: CCDC47; NbExp=2; IntAct=EBI-528644, EBI-720151;
CC       P58753; P51617: IRAK1; NbExp=2; IntAct=EBI-528644, EBI-358664;
CC       P58753; O43187: IRAK2; NbExp=2; IntAct=EBI-528644, EBI-447733;
CC       P58753; Q9NWZ3: IRAK4; NbExp=2; IntAct=EBI-528644, EBI-448378;
CC       P58753; O94822: LTN1; NbExp=2; IntAct=EBI-528644, EBI-1044684;
CC       P58753; Q99836: MYD88; NbExp=8; IntAct=EBI-528644, EBI-447677;
CC       P58753; P27986: PIK3R1; NbExp=3; IntAct=EBI-528644, EBI-79464;
CC       P58753; Q9Y3Z3: SAMHD1; NbExp=2; IntAct=EBI-528644, EBI-1054601;
CC       P58753; P58753: TIRAP; NbExp=2; IntAct=EBI-528644, EBI-528644;
CC       P58753; O00206: TLR4; NbExp=6; IntAct=EBI-528644, EBI-528701;
CC       P58753-2; P29466: CASP1; NbExp=5; IntAct=EBI-528654, EBI-516667;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:19948740}. Cell
CC       membrane {ECO:0000269|PubMed:19948740}. Membrane
CC       {ECO:0000269|PubMed:19948740}. Note=Colocalizes with DAB2IP at the
CC       plasma membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P58753-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P58753-2; Sequence=VSP_010765;
CC       Name=3;
CC         IsoId=P58753-3; Sequence=VSP_017239;
CC   -!- TISSUE SPECIFICITY: Highly expressed in liver, kidney, spleen, skeletal
CC       muscle and heart. Also detected in peripheral blood leukocytes, lung,
CC       placenta, small intestine, thymus, colon and brain.
CC   -!- DOMAIN: (Microbial infection) The TIR domain is structurally mimicked
CC       by the TIR domain of B.melitensis protein TcpB.
CC       {ECO:0000269|PubMed:24275656}.
CC   -!- PTM: Phosphorylated by IRAK1 and IRAK4. Also phosphorylated by BTK.
CC   -!- PTM: Polyubiquitinated. Polyubiquitination follows phosphorylation by
CC       BTK and leads to TIRAP degradation. {ECO:0000269|PubMed:16415872}.
CC   -!- POLYMORPHISM: Genetic variations in TIRAP have been proposed to
CC       influence susceptibility or resistance to invasive pneumococcal
CC       disease, malaria [MIM:611162], and tuberculosis [MIM:607948]. It may
CC       define the bacteremia susceptibility locus 1 (BACTS1) [MIM:614382]
CC       (PubMed:17322885, PubMed:19602285). Indeed it has been reported that
CC       heterozygous carriage of p.Ser180Leu in populations from the U.K.,
CC       Vietnam, and several African countries may confer protection against
CC       invasive pneumococcal disease, bacteremia, malaria, and tuberculosis
CC       (PubMed:17322885). However, analyzes of Russian, Ghanaian and
CC       Indonesian populations fail to replicate the association between
CC       p.Ser180Leu and susceptibility to tuberculosis formerly observed in
CC       West African and Algerian populations (PubMed:17322885,
CC       PubMed:18305471). {ECO:0000269|PubMed:17322885,
CC       ECO:0000269|PubMed:18305471, ECO:0000269|PubMed:19602285}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/tirap/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF406652; AAL01160.1; -; mRNA.
DR   EMBL; AF378129; AAL05627.1; -; mRNA.
DR   EMBL; AF410783; AAL05036.1; -; mRNA.
DR   EMBL; AY576785; AAT90417.1; -; mRNA.
DR   EMBL; AY576786; AAT90418.1; -; mRNA.
DR   EMBL; AY576787; AAT90419.1; -; mRNA.
DR   EMBL; AB446477; BAG55254.1; -; mRNA.
DR   EMBL; AK124298; BAG54027.1; -; mRNA.
DR   EMBL; AK313147; BAG35965.1; -; mRNA.
DR   EMBL; AY282416; AAP31973.1; -; Genomic_DNA.
DR   EMBL; AP001318; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471065; EAW67687.1; -; Genomic_DNA.
DR   EMBL; CH471065; EAW67689.1; -; Genomic_DNA.
DR   EMBL; BC032474; AAH32474.1; -; mRNA.
DR   CCDS; CCDS41731.1; -. [P58753-2]
DR   CCDS; CCDS8472.1; -. [P58753-1]
DR   RefSeq; NP_001034750.1; NM_001039661.1. [P58753-1]
DR   RefSeq; NP_001305705.1; NM_001318776.1. [P58753-2]
DR   RefSeq; NP_001305706.1; NM_001318777.1. [P58753-1]
DR   RefSeq; NP_683708.1; NM_148910.2. [P58753-2]
DR   RefSeq; XP_005271456.2; XM_005271399.3.
DR   RefSeq; XP_011540878.1; XM_011542576.2.
DR   RefSeq; XP_016872651.1; XM_017017162.1.
DR   PDB; 2NDH; NMR; -; A=79-221.
DR   PDB; 2Y92; X-ray; 3.01 A; A=79-221.
DR   PDB; 3UB2; X-ray; 2.40 A; A=78-221.
DR   PDB; 3UB3; X-ray; 2.75 A; A=78-221.
DR   PDB; 3UB4; X-ray; 3.10 A; A=78-221.
DR   PDB; 4FZ5; X-ray; 3.60 A; A/B=72-221.
DR   PDB; 4LQD; X-ray; 2.45 A; A=81-221.
DR   PDB; 5T7Q; NMR; -; A=15-35.
DR   PDB; 5UZB; EM; 7.00 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N=79-221.
DR   PDBsum; 2NDH; -.
DR   PDBsum; 2Y92; -.
DR   PDBsum; 3UB2; -.
DR   PDBsum; 3UB3; -.
DR   PDBsum; 3UB4; -.
DR   PDBsum; 4FZ5; -.
DR   PDBsum; 4LQD; -.
DR   PDBsum; 5T7Q; -.
DR   PDBsum; 5UZB; -.
DR   AlphaFoldDB; P58753; -.
DR   SMR; P58753; -.
DR   BioGRID; 125325; 44.
DR   DIP; DIP-33489N; -.
DR   IntAct; P58753; 43.
DR   MINT; P58753; -.
DR   STRING; 9606.ENSP00000376445; -.
DR   TCDB; 8.A.43.1.22; the neat-domain containing methaemoglobin heme sequestration (n-mhs) family.
DR   GlyGen; P58753; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P58753; -.
DR   PhosphoSitePlus; P58753; -.
DR   BioMuta; TIRAP; -.
DR   DMDM; 50403750; -.
DR   jPOST; P58753; -.
DR   MassIVE; P58753; -.
DR   PaxDb; P58753; -.
DR   PeptideAtlas; P58753; -.
DR   ProteomicsDB; 57101; -. [P58753-1]
DR   ProteomicsDB; 57102; -. [P58753-2]
DR   ProteomicsDB; 57103; -. [P58753-3]
DR   Antibodypedia; 19148; 583 antibodies from 40 providers.
DR   DNASU; 114609; -.
DR   Ensembl; ENST00000392678.7; ENSP00000376445.3; ENSG00000150455.15. [P58753-2]
DR   Ensembl; ENST00000392679.6; ENSP00000376446.1; ENSG00000150455.15. [P58753-1]
DR   Ensembl; ENST00000392680.6; ENSP00000376447.2; ENSG00000150455.15. [P58753-1]
DR   Ensembl; ENST00000479770.2; ENSP00000436967.1; ENSG00000150455.15. [P58753-1]
DR   Ensembl; ENST00000700488.1; ENSP00000515016.1; ENSG00000150455.15. [P58753-1]
DR   Ensembl; ENST00000700489.1; ENSP00000515017.1; ENSG00000150455.15. [P58753-1]
DR   Ensembl; ENST00000700490.1; ENSP00000515018.1; ENSG00000150455.15. [P58753-1]
DR   Ensembl; ENST00000700491.1; ENSP00000515019.1; ENSG00000150455.15. [P58753-2]
DR   Ensembl; ENST00000700492.1; ENSP00000515021.1; ENSG00000150455.15. [P58753-2]
DR   GeneID; 114609; -.
DR   KEGG; hsa:114609; -.
DR   MANE-Select; ENST00000392679.6; ENSP00000376446.1; NM_001318777.2; NP_001305706.1.
DR   UCSC; uc001qdl.2; human. [P58753-1]
DR   AGR; HGNC:17192; -.
DR   CTD; 114609; -.
DR   DisGeNET; 114609; -.
DR   GeneCards; TIRAP; -.
DR   HGNC; HGNC:17192; TIRAP.
DR   HPA; ENSG00000150455; Low tissue specificity.
DR   MalaCards; TIRAP; -.
DR   MIM; 606252; gene.
DR   MIM; 607948; phenotype.
DR   MIM; 611162; phenotype.
DR   MIM; 614382; phenotype.
DR   neXtProt; NX_P58753; -.
DR   OpenTargets; ENSG00000150455; -.
DR   PharmGKB; PA134972842; -.
DR   VEuPathDB; HostDB:ENSG00000150455; -.
DR   eggNOG; ENOG502S07Q; Eukaryota.
DR   GeneTree; ENSGT00510000048428; -.
DR   HOGENOM; CLU_091033_1_0_1; -.
DR   InParanoid; P58753; -.
DR   OMA; RWKRKYD; -.
DR   OrthoDB; 5392575at2759; -.
DR   PhylomeDB; P58753; -.
DR   TreeFam; TF330734; -.
DR   PathwayCommons; P58753; -.
DR   Reactome; R-HSA-1236974; ER-Phagosome pathway.
DR   Reactome; R-HSA-166058; MyD88:MAL(TIRAP) cascade initiated on plasma membrane.
DR   Reactome; R-HSA-5602498; MyD88 deficiency (TLR2/4).
DR   Reactome; R-HSA-5603041; IRAK4 deficiency (TLR2/4).
DR   SignaLink; P58753; -.
DR   SIGNOR; P58753; -.
DR   BioGRID-ORCS; 114609; 19 hits in 1161 CRISPR screens.
DR   ChiTaRS; TIRAP; human.
DR   GenomeRNAi; 114609; -.
DR   Pharos; P58753; Tbio.
DR   PRO; PR:P58753; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P58753; protein.
DR   Bgee; ENSG00000150455; Expressed in oviduct epithelium and 112 other tissues.
DR   ExpressionAtlas; P58753; baseline and differential.
DR   Genevisible; P58753; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProt.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030139; C:endocytic vesicle; ISS:BHF-UCL.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IDA:UniProt.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0032587; C:ruffle membrane; ISS:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0060090; F:molecular adaptor activity; IDA:UniProt.
DR   GO; GO:0140677; F:molecular function activator activity; IDA:UniProt.
DR   GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; ISS:BHF-UCL.
DR   GO; GO:0005080; F:protein kinase C binding; IPI:BHF-UCL.
DR   GO; GO:0030674; F:protein-macromolecule adaptor activity; NAS:BHF-UCL.
DR   GO; GO:0035663; F:Toll-like receptor 2 binding; IPI:BHF-UCL.
DR   GO; GO:0035662; F:Toll-like receptor 4 binding; IPI:BHF-UCL.
DR   GO; GO:0070935; P:3'-UTR-mediated mRNA stabilization; IDA:BHF-UCL.
DR   GO; GO:0007250; P:activation of NF-kappaB-inducing kinase activity; IMP:AgBase.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0071221; P:cellular response to bacterial lipopeptide; ISS:BHF-UCL.
DR   GO; GO:0071223; P:cellular response to lipoteichoic acid; ISS:BHF-UCL.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; ISS:BHF-UCL.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IBA:GO_Central.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0030099; P:myeloid cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; ISS:BHF-UCL.
DR   GO; GO:2000340; P:positive regulation of chemokine (C-X-C motif) ligand 1 production; ISS:BHF-UCL.
DR   GO; GO:2000343; P:positive regulation of chemokine (C-X-C motif) ligand 2 production; ISS:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:BHF-UCL.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IMP:BHF-UCL.
DR   GO; GO:0045089; P:positive regulation of innate immune response; IBA:GO_Central.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; ISS:BHF-UCL.
DR   GO; GO:0032738; P:positive regulation of interleukin-15 production; IDA:BHF-UCL.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IMP:BHF-UCL.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; IMP:BHF-UCL.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IMP:BHF-UCL.
DR   GO; GO:0090023; P:positive regulation of neutrophil chemotaxis; ISS:BHF-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:BHF-UCL.
DR   GO; GO:0031334; P:positive regulation of protein-containing complex assembly; IDA:BHF-UCL.
DR   GO; GO:0034137; P:positive regulation of toll-like receptor 2 signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0034141; P:positive regulation of toll-like receptor 3 signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0034145; P:positive regulation of toll-like receptor 4 signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IMP:BHF-UCL.
DR   GO; GO:0045088; P:regulation of innate immune response; IC:BHF-UCL.
DR   GO; GO:0032648; P:regulation of interferon-beta production; ISS:BHF-UCL.
DR   GO; GO:0032872; P:regulation of stress-activated MAPK cascade; IBA:GO_Central.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IDA:BHF-UCL.
DR   GO; GO:0035665; P:TIRAP-dependent toll-like receptor 4 signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0034142; P:toll-like receptor 4 signaling pathway; IDA:UniProt.
DR   DisProt; DP01768; -.
DR   Gene3D; 3.40.50.10140; Toll/interleukin-1 receptor homology (TIR) domain; 1.
DR   InterPro; IPR000157; TIR_dom.
DR   InterPro; IPR017279; Tol-interleuk_rcpt_adapt_Tirap.
DR   InterPro; IPR035897; Toll_tir_struct_dom_sf.
DR   PANTHER; PTHR22662; TIRAP; 1.
DR   PANTHER; PTHR22662:SF0; TOLL/INTERLEUKIN-1 RECEPTOR DOMAIN-CONTAINING ADAPTER PROTEIN; 1.
DR   Pfam; PF13676; TIR_2; 1.
DR   PIRSF; PIRSF037750; TIR_Tirap; 1.
DR   SUPFAM; SSF52200; Toll/Interleukin receptor TIR domain; 1.
DR   PROSITE; PS50104; TIR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Cytoplasm;
KW   Disulfide bond; Immunity; Inflammatory response; Innate immunity; Membrane;
KW   Phosphoprotein; Reference proteome; Ubl conjugation.
FT   CHAIN           1..221
FT                   /note="Toll/interleukin-1 receptor domain-containing
FT                   adapter protein"
FT                   /id="PRO_0000072547"
FT   DOMAIN          84..213
FT                   /note="TIR"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00204"
FT   REGION          1..82
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        40..82
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   DISULFID        89..134
FT                   /evidence="ECO:0000269|PubMed:21873236,
FT                   ECO:0000269|PubMed:24275656, ECO:0000312|PDB:4LQD"
FT   DISULFID        142..174
FT                   /evidence="ECO:0000269|PubMed:21873236,
FT                   ECO:0000269|PubMed:24275656, ECO:0000312|PDB:4LQD"
FT   VAR_SEQ         216..221
FT                   /note="YLQTLS -> CKLLQEGEGERDSATVSDLL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11526399,
FT                   ECO:0000303|PubMed:11544529, ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|Ref.4"
FT                   /id="VSP_010765"
FT   VAR_SEQ         221
FT                   /note="S -> WHLLYHGTPEIGVKLETENPCRASDSHKCDKRYRE (in isoform
FT                   3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_017239"
FT   VARIANT         9
FT                   /note="A -> P (does not affect NF-kappa-B activation and
FT                   TNF production; dbSNP:rs8177369)"
FT                   /evidence="ECO:0000269|PubMed:19509286, ECO:0000269|Ref.7"
FT                   /id="VAR_019143"
FT   VARIANT         13
FT                   /note="R -> W (does not affect NF-kappa-B activation and
FT                   TNF production; dbSNP:rs8177399)"
FT                   /evidence="ECO:0000269|PubMed:19509286, ECO:0000269|Ref.7"
FT                   /id="VAR_019144"
FT   VARIANT         55
FT                   /note="S -> N (does not affect NF-kappa-B activation and
FT                   TNF production; dbSNP:rs3802813)"
FT                   /evidence="ECO:0000269|PubMed:11544529,
FT                   ECO:0000269|PubMed:14702039"
FT                   /id="VAR_036691"
FT   VARIANT         96
FT                   /note="D -> N (hypomorphic variant resulting in impaired
FT                   NF-kappa-B activation and TNF production; loss of
FT                   interaction with MYD88; dbSNP:rs8177400)"
FT                   /evidence="ECO:0000269|PubMed:19509286, ECO:0000269|Ref.7"
FT                   /id="VAR_019145"
FT   VARIANT         180
FT                   /note="S -> L (the functional impact of this variant is
FT                   unclear; it has been reported both to affect interaction
FT                   with TLR2, hence attenuating TLR2 signal transduction and
FT                   to have no effect on NF-kappa-B activation and TNF
FT                   production; dbSNP:rs8177374)"
FT                   /evidence="ECO:0000269|PubMed:17322885,
FT                   ECO:0000269|PubMed:18305471, ECO:0000269|PubMed:19509286,
FT                   ECO:0000269|PubMed:19602285, ECO:0000269|Ref.7"
FT                   /id="VAR_019146"
FT   VARIANT         197
FT                   /note="V -> I (does not affect NF-kappa-B activation and
FT                   TNF production; dbSNP:rs7932976)"
FT                   /evidence="ECO:0000269|PubMed:19509286"
FT                   /id="VAR_061713"
FT   MUTAGEN         125
FT                   /note="P->H: Abolishes NF-kappa-B activation."
FT                   /evidence="ECO:0000269|PubMed:11526399,
FT                   ECO:0000269|PubMed:11544529"
FT   HELIX           17..28
FT                   /evidence="ECO:0007829|PDB:5T7Q"
FT   STRAND          83..91
FT                   /evidence="ECO:0007829|PDB:3UB2"
FT   HELIX           94..96
FT                   /evidence="ECO:0007829|PDB:3UB2"
FT   HELIX           97..108
FT                   /evidence="ECO:0007829|PDB:3UB2"
FT   TURN            109..111
FT                   /evidence="ECO:0007829|PDB:2NDH"
FT   STRAND          131..133
FT                   /evidence="ECO:0007829|PDB:3UB2"
FT   HELIX           135..139
FT                   /evidence="ECO:0007829|PDB:2NDH"
FT   STRAND          140..147
FT                   /evidence="ECO:0007829|PDB:3UB2"
FT   HELIX           149..153
FT                   /evidence="ECO:0007829|PDB:3UB2"
FT   HELIX           155..166
FT                   /evidence="ECO:0007829|PDB:3UB2"
FT   STRAND          168..179
FT                   /evidence="ECO:0007829|PDB:3UB2"
FT   HELIX           184..186
FT                   /evidence="ECO:0007829|PDB:3UB2"
FT   HELIX           189..193
FT                   /evidence="ECO:0007829|PDB:3UB2"
FT   HELIX           202..205
FT                   /evidence="ECO:0007829|PDB:3UB2"
FT   HELIX           206..217
FT                   /evidence="ECO:0007829|PDB:3UB2"
SQ   SEQUENCE   221 AA;  23883 MW;  44A8454D04704540 CRC64;
     MASSTSLPAP GSRPKKPLGK MADWFRQTLL KKPKKRPNSP ESTSSDASQP TSQDSPLPPS
     LSSVTSPSLP PTHASDSGSS RWSKDYDVCV CHSEEDLVAA QDLVSYLEGS TASLRCFLQL
     RDATPGGAIV SELCQALSSS HCRVLLITPG FLQDPWCKYQ MLQALTEAPG AEGCTIPLLS
     GLSRAAYPPE LRFMYYVDGR GPDGGFRQVK EAVMRYLQTL S
//
